A MULTI-CENTER, PHASE IB/II, OPEN LABEL, SINGLE ARM STUDY OF INOTUZUMAB OZOGAMICIN PLUS RITUXIMAB (R-CMC544) ALTERNATING WITH GEMCITABINE-OXALIPLATIN PLUS RITUXIMAB (R-GEMOX) IN PATIENTS AGED FROM 18 TO 80 YEARS WITH CD20 AND CD22 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN RELAPSE AFTER/REFRACTORY TO 1ST OR 2ND LINE TREATMENT, WHO ARE NO CANDIDATES FOR AUTOLOGOUS TRANSPLANT - CMC-R-GEMOX

YSARC0 个研究点目标入组 40 人开始时间: 2012年9月26日最近更新: 2016年8月8日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Histologically documented CD20 and CD22 positive diffuse large B-cell lymphoma, according to WHO classification. Prior CD20 and CD22 immunophenotyping is acceptable. If such prior documentation is not available, then the immunophenotype of the current disease must be documented by fine-needle aspirate or biopsy or by circulating CD20 and CD22 positive non-Hodgkin lymphoma (NHL) cells from peripheral blood during screening. In case of relapse or partial response the disease must be histologically or cytologically proven.
•Upon registration the anapath report confirming the diagnosis, must be available.
•During the trial the tumor tissue biopsy must be made available for confirmation of the disease.
•- In first or second relapse or refractory to first and/or second line treatment. Refractory is defined as less than PR to a prior rituximab containing regimen or relapse within 6 months of the last dose of a prior rituximab containing regimen.
•- Not eligible for autologous transplantation.
•- Previously treated with a chemotherapy regimen containing anthracyclines and rituximab.
•- Aged 18 - 80 years.
•- ECOG performance status 0 to 2.
•- Minimum life expectancy of 3 months.
•- Signed written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 32
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 8

排除标准

•- Burkitt, mantle cell and T-cell lymphomas.
•- Central nervous system or meningeal involvement by the lymphoma.
•- Contraindication to any drug contained in the R-GEMOX combination chemotherapy.
•- Treatment with any investigational drug within 30 days before the first planned cycle of chemotherapy and during the study.
•- Nitrosurea or mitomycin C administration within 6 weeks prior to study start.
•- Major debulking surgery within 3 weeks of treatment.
•- Any of the following lab abnormalities (unless related to the lymphoma or bone marrow infiltration):
•– Absolute neutrophil count (ANC) < 1.500/µL (1,5.109/L).
•– Platelet count < 100.000/µL (100.109/L).
•– Creatinine level > 150 µmol/L (1,7 mg/dL) or 1,5 – 2,0x ULN.
•– Total bilirubin level > 30 µmol/L (1,8 mg/dL) or 1,5x ULN.
•– Serum AST/SGOT or ALT/SGPT >2,5x ULN.
•- Documented infection with HIV, active hepatitis B or C infection.
•- Any serious active disease or co-morbid medical condition that, according to the investigator’s decision, will substantially increase the risk associated with the subject’s participation in the study. Prior history of malignancies other than lymphoma with the exception of non-melanoma skin tumors (basal cell or squamous cell carcinoma of the skin) or stage 0 (in situ) cervical carcinoma unless the subject has been disease-free for 5 or more years.
•- LVEF less than 50% (measured by echocardiography or scintigraphy).
•- Previous myocardial infarction or pulmonary hypertension within 6 months before the first dose of investigational product.
•- Congestive heart failure NYHA stage III or IV
•- Known chronic liver disease (eg. Cirrhosis) or suspected alcohol abuse.
•- Pregnant or lactating females
•- Men and women who are biologically capable of having children not willing to use an adequate method of birth control during the study and up to 18 months after the last dose of investigational product.
•- Adult patient unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness.

研究者

发起方

YSARC

相似试验

进行中（未招募）

4 期

A Study to Investigate the Efficacy and Safety of Faricimab in Patients with Polypoidal Choroidal Vasculopathy

JPRN-jRCT2031220231itin Jain, M.D.132

进行中（未招募）

1 期

A Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer in PD-L1-positive Populationresectable locally advanced or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-002488-91-SIF. Hoffmann-La Roche Ltd280

进行中（未招募）

1 期

A Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer in PD-L1-positive Populationresectable locally advanced or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-002488-91-HUF. Hoffmann-La Roche Ltd180

进行中（未招募）

1 期

EUCTR2019-002488-91-ITF. HOFFMANN - LA ROCHE LTD.280

进行中（未招募）

1 期

A Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer in PD-L1-positive Populatio

EUCTR2019-002488-91-PTF. Hoffmann-La Roche Ltd180